Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Shares Outstanding (Diluted Average) (2022 - 2025)

Silence Therapeutics' Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $141.7 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 2.12% to $141.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $141.7 million, a 2.12% increase, with the full-year FY2025 number at $141.7 million, up 2.12% from a year prior.
  • Shares Outstanding (Diluted Average) hit $141.7 million in Q4 2025 for Silence Therapeutics, roughly flat from $141.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for SLN hit a ceiling of $183.5 million in Q3 2024 and a floor of $113.3 million in Q4 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $147.9 million across 4 years, with a median of $141.7 million in 2025.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 21.91% in 2023 and later fell 22.77% in 2025.
  • Tracing SLN's Shares Outstanding (Diluted Average) over 4 years: stood at $113.3 million in 2022, then increased by 21.91% to $138.1 million in 2023, then rose by 0.46% to $138.8 million in 2024, then rose by 2.12% to $141.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SLN at $141.7 million in Q4 2025, $141.7 million in Q3 2025, and $141.7 million in Q2 2025.